Plain-English translation of NCT05681260 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial compares two different ways of giving chemotherapy to children and teens with newly diagnosed T-cell lymphoblastic lymphoma (a type of blood cancer). One group receives Capizzi escalating methotrexate, and the other receives high-dose methotrexate—both are common chemotherapy approaches. The trial wants to see which schedule works better and is safer for children with this disease.
Current treatments help about 75–85% of children with this type of lymphoma survive, but doctors have never directly compared these two chemotherapy schedules in this specific cancer. Understanding which approach is best could improve survival rates and reduce long-term side effects like secondary cancers.
You likely qualify if…
You likely don't qualify if…
After an initial phase of chemotherapy, you will be randomly assigned to receive either Capizzi escalating methotrexate or high-dose methotrexate during the next phase of treatment. You will also receive additional chemotherapy blocks, medicines injected into the spinal fluid, and maintenance therapy over several months. You'll have regular hospital visits for treatment and blood tests to monitor how you're responding.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China